AIM: To investigate whether serum vascular endothelial growth factor-C (SVEGF-C), VEGF-C, and lymphatic vessel density (LVD) in tumor tissues are related to lymph node metastasis (LNM) and prognosis in gastric cancer. METHODS: SVEGF-C levels of 80 gastric cancer patients and 20 healthy donors were examined using ELISA. VEGF-C expression and LVD were examined using immunohistochemical staining. Kaplan-Meier survival analysis was performed to determine their influence on the prognosis of the patients. RESULTS: The SVEGF-C level in gastric cancer patients (595.9 +/- 201.0 ng/L) was significantly higher (P = 0.000) than controls (360.0 +/- 97.4 ng/L). Both SVEGF-C and LVD were significantly higher in poorly differentiated adenocarcinomas, T3 and T4, LNM, distant metastasis, and pTNM groups III and IV (P = 0.000). The sensitivity and specificity of SVEGF-C for predicting LNM were 82.8% and 81.8%, respectively (cut-off = 542.5 ng/L). The positive expression rate of VEGF-C was significantly higher in cancerous than in normal tissues (65% vs 20%; P = 0.001). VEGF-C expression up-regulation was significantly related to differentiation, depth of invasion, LNM, distant metastasis, and pTNM stage (P = 0.000). LVD was 10.7 +/- 3.1/200 HP in the experimental group vs 4.9 +/- 1.3/200 HP in controls (P = 0.000); LVD in cancerous tissues with and without LNM was 12.0 +/- 2.7/200 HP vs 7.6 +/- 0.5/200 HP, respectively (P = 0.000). SVEGF-C and LVD were significantly higher in VEGF-C positive than in negative patients (P = 0.000); SVEGF-C level was related to LVD (P = 0.000). Kaplan-Meier survival analysis factors predicating poor prognosis were: SVEGF-C level (P = 0.001), VEGF-C expression and LVD (both P = 0.000). CONCLUSION: SVEGF-C level, VEGF-C and LVD are related to LNM and poor prognosis of patients with gastric cancer. SVEGF-C may be a biomarker for LNM in gastric cancer.
AIM: To investigate whether serum vascular endothelial growth factor-C (SVEGF-C), VEGF-C, and lymphatic vessel density (LVD) in tumor tissues are related to lymph node metastasis (LNM) and prognosis in gastric cancer. METHODS:SVEGF-C levels of 80 gastric cancerpatients and 20 healthy donors were examined using ELISA. VEGF-C expression and LVD were examined using immunohistochemical staining. Kaplan-Meier survival analysis was performed to determine their influence on the prognosis of the patients. RESULTS: The SVEGF-C level in gastric cancerpatients (595.9 +/- 201.0 ng/L) was significantly higher (P = 0.000) than controls (360.0 +/- 97.4 ng/L). Both SVEGF-C and LVD were significantly higher in poorly differentiated adenocarcinomas, T3 and T4, LNM, distant metastasis, and pTNM groups III and IV (P = 0.000). The sensitivity and specificity of SVEGF-C for predicting LNM were 82.8% and 81.8%, respectively (cut-off = 542.5 ng/L). The positive expression rate of VEGF-C was significantly higher in cancerous than in normal tissues (65% vs 20%; P = 0.001). VEGF-C expression up-regulation was significantly related to differentiation, depth of invasion, LNM, distant metastasis, and pTNM stage (P = 0.000). LVD was 10.7 +/- 3.1/200 HP in the experimental group vs 4.9 +/- 1.3/200 HP in controls (P = 0.000); LVD in cancerous tissues with and without LNM was 12.0 +/- 2.7/200 HP vs 7.6 +/- 0.5/200 HP, respectively (P = 0.000). SVEGF-C and LVD were significantly higher in VEGF-C positive than in negative patients (P = 0.000); SVEGF-C level was related to LVD (P = 0.000). Kaplan-Meier survival analysis factors predicating poor prognosis were: SVEGF-C level (P = 0.001), VEGF-C expression and LVD (both P = 0.000). CONCLUSION:SVEGF-C level, VEGF-C and LVD are related to LNM and poor prognosis of patients with gastric cancer. SVEGF-C may be a biomarker for LNM in gastric cancer.
Authors: Y Yonemura; Y Endo; H Fujita; S Fushida; I Ninomiya; E Bandou; K Taniguchi; K Miwa; S Ohoyama; K Sugiyama; T Sasaki Journal: Clin Cancer Res Date: 1999-07 Impact factor: 12.531
Authors: Andres A Roma; Cristina Magi-Galluzzi; Melinda A Kral; Tao T Jin; Eric A Klein; Ming Zhou Journal: Mod Pathol Date: 2006-03 Impact factor: 7.842
Authors: Subbi P Mathur; Rajesh S Mathur; Elizabeth A Gray; Derrick Lane; Paul G Underwood; Matthew Kohler; William T Creasman Journal: Gynecol Oncol Date: 2005-09 Impact factor: 5.482
Authors: Marlys H Witte; Michael T Dellinger; Donald M McDonald; S David Nathanson; Francesco M Boccardo; Corradino C C Campisi; Jonathan P Sleeman; Jeffrey E Gershenwald Journal: J Surg Oncol Date: 2011-05-01 Impact factor: 3.454
Authors: Diego Pérez; Alexander Rohde; Gonzalo Callejón; Elisabeth Pérez-Ruiz; Isabel Rodrigo; Francisco Rivas-Ruiz; Belen Ramos; Francisco Medina; Rosa Villatoro; Maximino Redondo; Irene Zarcos; Claudio Maañón; Antonio Rueda Journal: Tumour Biol Date: 2015-06-24
Authors: Mansour-S Al-Moundhri; A Al-Shukaili; M Al-Nabhani; B Al-Bahrani; I-A Burney; A Rizivi; S-S Ganguly Journal: World J Gastroenterol Date: 2008-06-28 Impact factor: 5.742